Drugs / omilancor
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04835168 | Jan → Apr 2022 | eosinophilic esophagitis | NImmune Biopharma | Withdrawn | No outcome recorded |
| Phase 1 | NCT03860571 | Jul → Sep 2018 | — | NImmune Biopharma | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT05057273 | Nov 2021 → Feb 2022 | Crohn disease | NImmune Biopharma | Withdrawn | No outcome recorded |
| Phase 2 | NCT03870334 | May 2021 → Aug 2022 | Crohn disease | NImmune Biopharma | Terminated | No outcome recorded |
| Phase 2 | NCT03861143 | Aug 2019 → Dec 2020 | ulcerative colitis | NImmune Biopharma | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | omilancor | “This is a phase 2, randomized, double-blind, multicenter study to assess the therapeutic efficacy, safety, and mechanisms of omilancor (BT-11) in patients with moderate to...” NCT05057273 ↗ |
| Known as | BT-11 | “This is a phase 2, randomized, double-blind, multicenter study to assess the therapeutic efficacy, safety, and mechanisms of omilancor (BT-11) in patients with moderate to...” NCT05057273 ↗ |
| Modality | Small molecule | — CHEMBL4788758 ↗ |
| Route | Oral | “The mode administration will be oral tablet.” NCT03860571 ↗ |